- Boston Scientific (NYSE:BSX) has entered into a collaboration with Truveta, which provides de-identified health data on more than 65M patients, to analyze patient outcomes related to the use of the device company's products.
- The first analysis under the partnership will be on patient outcomes related to the use of Boston Scientific (BSX) products indicated for treatment of peripheral artery disease.
- The company noted that the data provided by Truveta will help address the disparities in access to healthcare treatments.
- Seeking Alpha's Quant Rating views Boston Scientific as a hold with high grades for profitability and momentum.
Boston Scientific in partnership with Truveta on patient outcomes to improve care
Recommended For You
More Trending News
About BSX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BSX | - | - |
Boston Scientific Corporation |